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Abstract 
 
Background: Cardiovascular disease is a major cause of 
morbidity and mortality in hemodialysis patients, there is 
increasing evidence that platelets are major contributors 
to atherosclerosis, which is mediated through F11 
receptors. 
Methods: Our study included 40 hemodialysis patients 
divided into two groups: 
Group 1: included 20 hemodialysis patients with 
ischemic heart disease (IHD), Group 2: included 20 
hemodialysis patients without ischemic heart disease, 
they were compared with 20 age and sex matched 
controls, soluble F11 receptor (sF11R) and high 
sensitivity C-reactive protein (hs-CRP) were measured 
by enzyme-linked immunosorbent assay (ELISA). 
Results: sF11R was significantly higher in hemodialysis 
patients than controls; it showed significant difference 
between group 1, group 2 patients and controls. sF11R 
showed significant positive correlation with hs-CRP . 
Conclusion: sF11R can be considered a marker of IHD 
in hemodialysis patients. 
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Introduction 
 
Since 1960S, cardiovascular disease is the most common 
cause of death in patients with ESRD. The 
cardiovascular mortality rate in ESRD patients on 
dialysis is approximately 10 to 20 times higher than in 
the general population [1].  
    
Acute myocardial infarction accounted for 14 deaths per 
1000 patient/year whereas arrhythmia and sudden death 
accounted for 46.5 deaths per 1000 patient/year [2]. 
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The probability that a dialysis patient will develop 
ischemic heart disease or cardiac failure is about 20% per 
year [3]. Many risk factors predispose to ischemic heart 
disease in renal failure patients such as systemic arterial 
hypertension [4], diabetes mellitus [5], dyslipidemias [6], 
inflammation [7], and vascular calcification [8]. 
Many inflammatory markers are up regulated in 
hemodialysis patients as interleukin 6, and high 
sensitivity C - reactive protein, so these markers link the 
pathogenesis of atherosclerosis to chronic inflammation 
[9]. It is now accepted that platelets contribute to acute or 
chronic inflammatory events, leading to atherosclerotic 
lesion formation. There is a growing body of evidence 
showing that the interaction between platelets and 
endothelial cells contributes significantly to the 
pathogenesis of atherosclerosis [10].  
Platelet adhesion to the inflamed endothelium triggers 
the formation of thrombi leading to atherosclerotic 
lesions [11].   
A key molecule identified as critical for platelet adhesion 
to an activated endothelial surface is the F11 receptor 
(F11R) [12]. 
F11 receptor (F11R/JAM-A) is a member of the 
immunoglobulin super family. The F11 receptor (F11R) 
was described first in human platelets in 1990 [12]. In 
1998, amino acid sequences homologous to the F11R 
were found in a protein present within tight junctions of 
endothelial cells [13] where the molecule was called 
Junctional Adhesion Molecule (JAM), F11R is a 32/35 
kDa protein duplex that serves as a receptor for a 
functional monoclonal antibody that activates platelets, 
This monoclonal antibody binds to the platelet F11 
receptor resulting in granule secretion and aggregation 
[14].        
A potential mechanism of finding a soluble fragment of 
the extracellular domain
 
of   F11R   is that
 
F11R is shed 
from endothelial cells and/or platelets through
 
a pathway 
involving enzymatic cleavage at a site in close proximity
 
to the membrane, resulting in the release of the 
extracellular
 
domain of F11R into the circulation [15]. 
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Material and methods 
 
The present study included 40 chronic renal failure 
patients on regular hemodialysis from dialysis center at 
Cairo University in the period from May 2008 to June 
2009. 
Patients receive dialysis sessions for 4 hours, three times 
weekly through arteriovenous fistula, mean age ± SD 
was 47.5±10.4, 50% were males and 50% were females. 
Duration of dialysis ranged from 1 year to 15 years with 
(mean±SD) 17.1±3.5 years. Patients receive heparin 
during dialysis sessions. Patients were excluded if they 
take drugs which inhibit platelet function as asprin, 
clopedrogrel.  None of our patients were diabetics. 
They were divided into two groups: 
Group 1: Included 20 patients who are known to have 
coronary artery disease, which was diagnosed on the 
basis of history, ECG, echocardiography, coronary 
angiography which was performed in selected patients. 
Group 2: Included 20 patients without ischemic heart 
disease (IHD). 
They were compared with 20 age and sex matched 
healthy controls.  
All patients were subjected to the followings: 
 Full history taking.  
 Full clinical examination.  
 Pre dialysis serum creatinine, blood urea, calcium 
(Ca), phosphorus (P), calcium×phosphorus(Ca×P) 
product, hemoglobin, platelet count. 
 High sensitivity C-reactive protein (hs-CRP) by 
Enzyme linked Immunosorbent assay technique 
(ELISA) [16]. 
 Soluble F11 receptor level was measured in plasma 
by sandwich ELISA using commercially available 
ELISA kits, F11R (R&D Systems; and BD 
Biosciences, San Jose, California) according to 
manufacturer's instructions [17]. 
 ECG. 
 Echocardiography. 
 Coronary angiography in selected patients with 
ischemic heart disease. 
 
Statistical analysis 
 
Analysis of data was done by IBM computer using SPSS 
(statistical program for social science version 12) as 
follows  
 Chi-square test was used to compare qualitative 
variables between groups. 
 Unpaired t-test was used to compare quantitative 
variables, in parametric data (SD<50% mean) 
 One way ANOVA (analysis of variance) test was 
used to compare more than two groups in parametric 
quantitative data. 
 Correlation coefficient test was used to rank 
different variables against each other positively or 
inversely. 
 ROC (receiver operator characteristic curve was 
used to find out the best cut off value of certain 
variable). 
 
Results 
 
Table 1. Laboratory data of hemodialysis (HD) patients.  
 
 
Range 
 
Mean ±SD 
 
Laboratory data 
 
 
122-387 
 
231±78 
 
Platelets (x1000/ml) 
6-15 9.7±2.5 Hemoglobin (gm/dl) 
7.2-9 8.1±0.6 Calcium (mg/dl) 
2.7-4.6 3.8±1.3 Phosphorus (mg/dl) 
18-25 20±2.3 Ca × P 
70-150 130±23 Urea (mg/dl) 
5.1-15.2 9.3±2.1 Creatinine (mg/dl) 
 
 
Table 2. Comparison between HD patients and controls regarding 
sF11R. 
 
 
P-value 
 
Controls 
 
HD patients 
 
 
<0.01 
 
30.1±6 
 
92.6±31 
 
sF11 R(pg/ml) 
 
Table 2 shows that there was statistically significant 
difference in sF11R between HD patients and controls.  
 
Table 3. Comparison between IHD,  non IHD hemodialysis patients 
and controls regarding sF11R and hs-CRP. 
 
 
P-value 
 
Controls 
 
Non IHD 
  
IHD 
 
Variable 
 
 
<0.01 
 
30.1±6 
 
83±32 
 
101±29 
 
sF11R(pg/ml) 
<0.01 0.83±0.20 3.12±1.15 5.74±1.36 hs-CRP(mg/dl) 
 
 
Table 3 shows that there were statistically significant 
differences in sF11R and hs-CRP between HD patients 
with IHD, HD patients without IHD and controls. 
 
Table 4. Correlation between sF11R and clinical and laboratory data. 
 
 
Variable 
 
               sF11R 
_______________________ 
r                          p-value 
 
 
Age 
 
0.04 
 
>0.05 
Duration of the disease 0.13 >0.05 
Hypertension 0.09 >0.05 
IHD 0.40 <0.05 
Platelets -0.12 >0.05 
Hemoglobin -0.15 >0.05 
Calcium -0.37 <0.05 
Phosphorus -0.09 >0.05 
Ca×P  -0.13 >0.05 
Urea 0.35 >0.05 
Creatinine 0.30 >0.05 
hs-CRP 
 
0.39 <0.05 
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Table 4 shows that sF11R had significant positive 
correlation with the presence of ischemic heart disease 
and  hs-CRP, and significant negative correlation with 
serum calcium level, with no significant correlation with 
other clinical and laboratory findings. 
 
Table 5. Sensitivity, specificity, PPV, NPV and accuracy of sF11R. 
  
 
P-value 
 
Variables 
 
 
40 pg/ml 
 
Best cut-off value 
97.5% Sensitivity 
95% Specificity 
97.5% PPV 
95% NPV 
96% Accuracy 
 
 
Table 5 shows that sF11R is considered a valid marker 
for prediction of ischemic heart disease in hemodialysis 
patients with high sensitivity, specificity, and accuracy.  
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Fig. 1. Comparison between cases and controls as regard sF11R. 
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Fig. 2. Comparison between IHD, non IHD hemodialysis patients and 
controls as regard sF11R. 
 
 
 
Fig. 3. Correlation between sF11R versus hs-CRP among the studied 
cases by linear regression curve. 
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Fig. 4. Receiver operator characteristic curve for sF11R. Area under the 
curve = 97%. 
 
Upon one year follow up, 6 out of the 20 dialysis patients 
with IHD developed myocardial infarction or unstable 
angina, for which they were admitted to coronary care 
unit, 4 of these patients died, and 2 patients improved by 
treatment. Their (mean ±SD) sF11R was (123.73±18.87), 
which is higher but statistically non significant than those 
with IHD patients who did not develop recent cardiac 
events (115.58±16.24). 
 
Discussion 
 
Cardiovascular disease is a major   cause of morbidity 
and mortality in haemodialysis patients, there is 
increasing evidence that platelets are involved in 
atherosclerotic plaque formation via F11R [18]. The 
activation of F11R appears to trigger two pathways: The 
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first includes cross linking of the F11R to the FcR11 
and plays a role in the aggregation of platelets but not 
adhesion [19], The second pathway involves the binding 
of the constitutively expressed F11R of platelets to the 
up-regulated F11R located on the luminal surface of the 
inflamed endothelium through hemophilic interactions 
[20]. 
Activation of Fl IR has been found to cause sensitization 
of platelets, increasing the platelet reactivity to 
circulating platelet receptor agonists such as adenosine 
diphosphate and thrombin [21]. 
Subsequently, following the adhesion of platelets to the 
inflamed endothelium through F11R, subthreshold 
concentrations of naturally circulating agonists would be 
expected to cause stable buildup of platelet plaques, 
thereby contributing to atherosclerosis [19]. 
Our study revealed that sF11R was significantly higher 
in hemodialysis patients than in normal controls; it 
showed significant difference between hemodialysis 
patients with IHD, hemodialysis patients without IHD 
and normal controls. 
sF11R  showed significant positive correlation with 
inflammatory marker hs- CRP, and significant negative 
correlation with serum calcium, while no significant 
correlation was found with other study variables, 
including age, duration of the disease, presence of 
hypertension, phosphorus, Ca×P product, platelet count 
or hemoglobin level. 
Salifu and his colleagues [15] reported that sF11 R level 
was significantly higher in hemodialysis patients than 
normal controls, sF11R had significant positive 
correlation with inflammatory markers as  tumor necrosis 
factor  (TNF-), interleukin-6 (IL-6), and interleukin-
10 (IL-10), but no significant correlation was found 
between sF11R and hs-CRP. 
ROC curve was constructed and revealed that sF11R can 
be considered as sensitive and specific marker of IHD in 
hemodialysis patients with 97.5% sensitivity and 95% 
specificity.   
Follow up of our patients for one year revealed that 6 
patients of IHD group developed acute coronary 
syndrome 4of them died, these patients had higher levels 
(although statistically not significant) of s F11R than 
IHD patients who did not develop cardiac events through 
one year follow up. 
 
Conclusion 
 
sF11R can be considered as sensitive and specific marker 
of IHD in hemodialysis patients, it could be also a 
marker of cardiovascular morbidity and mortality, but 
further studies are needed including larger number of 
patients and longer periods of follow up. 
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